Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects

NCT05203692 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT05203692
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05203692 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Subjects- and Investigator-Blinded, Sponsor-Unblinded, Placebo-Controlled, Randomized, Sequential Cohort Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of DS-7011a in Healthy Subjects
Lead sponsor
Daiichi Sankyo
Phase
Phase 1
Overall status
Completed
Start date
February 2, 2022
Completion date
March 22, 2023
Enrollment
80 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus